MCRB vs. ORMP, GNLX, BRNS, CNTB, MIST, RVPH, ALLK, ANIX, RNAC, and IOBT
Should you be buying Seres Therapeutics stock or one of its competitors? The main competitors of Seres Therapeutics include Oramed Pharmaceuticals (ORMP), Genelux (GNLX), Barinthus Biotherapeutics (BRNS), Connect Biopharma (CNTB), Milestone Pharmaceuticals (MIST), Reviva Pharmaceuticals (RVPH), Allakos (ALLK), Anixa Biosciences (ANIX), Cartesian Therapeutics (RNAC), and IO Biotech (IOBT). These companies are all part of the "pharmaceutical preparations" industry.
Oramed Pharmaceuticals (NASDAQ:ORMP) and Seres Therapeutics (NASDAQ:MCRB) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, dividends, analyst recommendations, community ranking, risk, valuation, profitability, institutional ownership and earnings.
Oramed Pharmaceuticals' return on equity of 0.00% beat Seres Therapeutics' return on equity.
Oramed Pharmaceuticals has higher earnings, but lower revenue than Seres Therapeutics. Seres Therapeutics is trading at a lower price-to-earnings ratio than Oramed Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
12.7% of Oramed Pharmaceuticals shares are owned by institutional investors. Comparatively, 59.3% of Seres Therapeutics shares are owned by institutional investors. 12.0% of Oramed Pharmaceuticals shares are owned by insiders. Comparatively, 5.1% of Seres Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Seres Therapeutics received 207 more outperform votes than Oramed Pharmaceuticals when rated by MarketBeat users. However, 74.82% of users gave Oramed Pharmaceuticals an outperform vote while only 72.40% of users gave Seres Therapeutics an outperform vote.
Oramed Pharmaceuticals has a beta of 1.81, meaning that its share price is 81% more volatile than the S&P 500. Comparatively, Seres Therapeutics has a beta of 2.23, meaning that its share price is 123% more volatile than the S&P 500.
Seres Therapeutics has a consensus target price of $6.50, suggesting a potential upside of 687.88%. Given Oramed Pharmaceuticals' higher possible upside, analysts plainly believe Seres Therapeutics is more favorable than Oramed Pharmaceuticals.
In the previous week, Oramed Pharmaceuticals had 2 more articles in the media than Seres Therapeutics. MarketBeat recorded 2 mentions for Oramed Pharmaceuticals and 0 mentions for Seres Therapeutics. Seres Therapeutics' average media sentiment score of 1.38 beat Oramed Pharmaceuticals' score of 0.10 indicating that Oramed Pharmaceuticals is being referred to more favorably in the media.
Summary
Oramed Pharmaceuticals beats Seres Therapeutics on 9 of the 16 factors compared between the two stocks.
Get Seres Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for MCRB and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding MCRB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Seres Therapeutics Competitors List
Related Companies and Tools
